Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxLow-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Combination Therapy Gets Fast Tracked: 177Lu-PSMA-617 (Pluvicto) Plus TRE-515
/in Clinical Trial, Metastatic, Phase 1/by MaxEarly Results of Gedatolisib and Darolutamide in mCRPC Treatment
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: WGc-043, Exploring a New mRNA Vaccine for EBV-Positive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Results for Imaging Agent Cu-61 NuriPro Shows Promise for Future Theranostic Option Cu-67
/in Clinical Trial, Metastatic, Phase 1/by MaxAt the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a promising phase I clinical trial results were presented for Cu-61 NuriPro, a next-generation PET imaging agent specifically designed for patients with PSMA-positive metastatic prostate cancer. This agent targets prostate-specific membrane antigen (PSMA), a protein commonly overexpressed in prostate cancer cells, making […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026